Deep Lens has extended one of the world’s first digital pathology cloud platforms that for over ten years has allowed pathology groups to collaborate on groundbreaking cancer research across dozens of cancer types.  

BioPharma companies turn to Deep Lens to identify patients for clinical trials in real time, at the time of diagnosis. These proprietary upstream methods allow for high recruitment rates, sooner, to compress study timelines.

Deep Lens’ accurate and unique AI methods are also used in translational research by pharma and biotech companies globally where the anatomy of the disease and it’s progression can be modeled with Deep Lens’ cutting edge deep learning methods.